Navigation Links
ADVENTRX Settles Dispute With Former Licensee
Date:6/30/2008

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that it settled its dispute with Theragenex, LLC and its Chairman and President and Chief Executive Officer for payments aggregating $600,000, which payments the Company has received in full. The parties have agreed to jointly move to dismiss the underlying arbitration action and all related claims and counterclaims, with prejudice. In addition, in connection with dismissing the arbitration, the Company and Theragenex will release each other from any and all claims related to their past relationship.

In October 2007, the Company filed a demand for arbitration against Theragenex (doing business as TRx Pharma, LLC and/or TRx Pharmaceuticals, LLC) and its founder, Chairman and President and Chief Executive Officer in his individual capacity as the alter ego of Theragenex, seeking damages of up to $10 million with respect to breach of a license agreement, dated October 20, 2006, between the Company and Theragenex. In November 2007, Theragenex responded to the Company's demand, asserting numerous affirmative defenses, counterclaiming intentional misrepresentation, negligent misrepresentation and rescission and seeking a refund of its initial $500,000 payment under the license agreement, plus interest, rescission of the license agreement and that the Company pay its reasonable attorneys' fees and costs associated with the action.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2. ADVENTRX Appoints Vice President of Manufacturing
3. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
6. Eric K. Rowinsky Joins ADVENTRX Board of Directors
7. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
8. ADVENTRX Announces Consolidation of Clinical and Management Positions
9. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
10. ADVENTRX Appoints Vice President of Commercialization
11. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Diego, Calif. (PRWEB) , ... May 25, 2016 , ... ... Diego area and has consistently been rated one of its top attractions. Fortune ... the globe to participate in a unique and intimate team-building experience. , Each event ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven ... Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for ... designation granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating ...
(Date:5/24/2016)... ... 2016 , ... Media Cybernetics, global image analysis leader, announces ... reflects a results-driven revitalization for a company with a renewed focus on innovation ... crisp, refreshed logo and a new web presence. , “I believe that the ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):